SeaStar Medical Holding Corporation (ICU), a commercial-stage medical device company, is slated to host a conference call on Wednesday at 4.30 p.m. ET, to provide business updates and pipeline progress.
The company focuses on advancing cell-directed extracorporeal therapy for treating hyperinflammation, which includes approved Quelimmune, a selective cytopheretic device (SCD).
The SCD has received breakthrough designations from the FDA for 4 indications namely Adult Acute kidney Injury, Cardiorenal Syndrome, Hepatorenal Syndrome, and Chronic systemic Inflammation in End-stage renal disease.
NEUTRALIZE-AKI trial is currently evaluating the safety and efficacy of SCD in Adult Acute Kidney injury patients requiring CRRT (Continuous Renal Replacement Therapy).
ICU is currently trading at $2.17, up 0.46%.
For comments and feedback: editorial@rttnews.com